Insight

Jul 12, 2024, 11:24

What comes after sotorasib and adagrasib?

Aakash Desai, Thoracic/Phase 1 Oncologist at UAB O’Neal Comprehensive Cancer Center, shared a post on X about a recent paper titled “The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?” published in Lung Cancer Journal.

Authors: Yuko Oya, Kazuyoshi Imaizumi, Tetsuya Mitsudomi. .

“KRAS, once ‘undruggable,’ now sotorasib and adagrasib, but efficacy is limited.

Next-gen KRAS G12C/non-G12Ci and innovative approaches like molecular shielding and protein degradation are on the horizon!

Combos with SHP2/SOS1 inhibitors, chemo, or immune checkpoint inhibitors are being explored to tackle resistance.
Great review in Lung Cancer Journal.”

Source: Aakash Desai/X

Aakash Desai Adagrasib cancer G12C/non-G12Ci Kazuyoshi Imaizumi KRAS Lung Cancer Journal molecular shielding OncoDaily Oncology Research Sotorasib Tetsuya Mitsudomi UAB O'Neal Comprehensive Cancer Center Yuko Oya

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage